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Summary 
Interferons and monoclonal antibodies are among the most promising biological approaches to cancer 
treatment which have so far been investigated. Both natural and recombinant interferon-alpha preparations 
have shown activity in a number of trials in hematologic malignancies, even in previously treated patients; 
activity in solid tumors, however, has been limited. Unconjugated monoclonal antibodies have been safely 
administered in several small trials and have had therapeutic value on occasion. In spite of a number of 
remaining problems and questions, monoclonal antibodies and their conjugates seem likely to find a number 
of distinct roles in cancer treatment; elimination of micrometastases and purging of bone marrow for grafting 
may be among these roles. 
Introduction Interferon 
Progress has been made over the past 5 years to- 
ward the development of specific biological ap- 
proaches to the treatment of cancer. The tech- 
niques of genetic engineering and mass cell culture, 
and improved techniques in protein and nucleic 
acid sequencing, have made available biologics as 
highly purified molecules. The most definitive in- 
vestigations have been carried out with natural and 
cloned interferon-c~ preparations, and it is clear 
that they are capable of inducing responses pri- 
marily in patients with certain types of lymphomas 
and leukemias. Preliminary trials with murine 
monoclonal antibodies have demonstrated excel- 
lent in vivo tumor localization and transient clinical 
responses; durable responses are rare events. Anti- 
bodies conjugated to drugs, toxins, and isotopes 
have greater antitumor activity in vitro and in ani- 
mal models, and clinical trials are currently under 
way. 
Interferons are a family of proteins produced by 
cells in response to virus, double-stranded ribonu- 
cleic acid, antigens, and mitogens (1). In addition 
to antiviral activity (2), the interferons have pro- 
found effects on a number of components of the 
immune system, including B, T, and natural killer 
cells and macrophages (3, 4), and have anti- 
proliferative activity (4, 5). With respect to the 
interferons and cancer therapy, it is still unclear 
whether the interferons work primarily by their 
antiproliferative activity or through alterations of 
immune responses. It is clear, however, from both 
preclinical and clinical studies that interferons have 
antitumor activity in a number of tumor systems (6, 
7). 
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Leukernias and lymphomas 
The most extensively studied interferons clinically 
are the natural and recombinant interferon-c~ prep- 
arations. At the National Cancer Institute we re- 
cently completed a phase II interferon trial for 
previously treated patients with non-Hodgkin's 
lymphoma, chronic lymphocytic leukemia, and cu- 
taneous T cell lymphoma (mycosis fungoides). We 
chose these diseases because earlier trials with nat- 
ural interferon-a preparations suggested they 
would be responsive (8-10). Patients were treated 
with highly purified recombinant leukocyte A in- 
terferon (Hoffmann-La Roche, Nutley, New 
Jersey) at 50 × 106 U/m 2 body surface area three 
times weekly by the intramuscular route; the dose 
and schedule were based on the maximum toler- 
ated dose from our phase I study (11). Patients were 
treated for three months, and dose reductions to 
50% and then 10% of the starting dose were made 
based on unacceptable toxicity (e.g., fatigue, 
anorexia, leukopenia, elevated hepatic trans- 
aminases). 
Eighty-four patients were entered on our phase 
II lymphoma/leukemia trial. Forty-five of these 
patients had non-Hodgkin's lymphoma (12), 20 had 
cutaneous T cell lymphoma (13), and 19 had 
chronic lymphocytic leukemia (14). Major toxic 
reactions observed were fever, chills, fatigue, and 
anorexia. The average duration of therapy was 2.5 
weeks at the 100% dose and 6.5 weeks at the 50% 
dose. Fatigue was the most common reason for 
dose reduction. 
Our results indicated significant antitumor ac- 
tivity for recombinant leukocyte A interferon in 
patients with low grade and intermediate grade 
histology non-Hodgkin's lymphoma classified by 
the Working Formulation (15), and for patients 
with cutaneous T cell lymphoma (Table 1). Fifty- 
five percent of the patients with low grade and 
intermediate grade histology non-Hodgkin's lym- 
phoma and nearly 50% with cutaneous T cell lym- 
phoma responded with either partial or complete 
responses, All responding patients were main- 
tained on recombinant leukocyte A interferon 
therapy; the median duration of response was 8 
months for non-Hodgkin's lymphoma and 6 
months for cutaneous T cell lymphoma. The five 
complete responders with low grade and inter- 
mediate grade histology non-Hodgkin's lymphoma 
were shown to be tumor free in sites of previous 
disease by noninvasive studies and biopsies where 
indicated. Responses included resolution of bone 
marrow disease as well as bulky disease in the 
mediastinum and retroperitoneum (12, 16). The 
responses in patients with cutaneous T cell lym- 
phoma included reductions of the size of skin pla- 
ques and tumors, lymph nodes, and circulating 
Sdzary cells. It was particularly interesting that all 
of the responding patients had very advanced dis- 
ease and had failed multiple courses of combina- 
tion chemotherapy. Recombinant leukocyte A in- 
terferon was not effective in this dose schedule for 
patients with advanced chronic lymphocytic leuke- 
mia, with only 2 partial responses and 11 of 18 
evaluable patients progressing while on interferon 
therapy (14). 
Table 1. Clinical Responses in the National Cancer Institute Phase II Recombinant Leukocyte A Interferon Trials for Lymphoprolifera- 
tive Disorders 
Disease* Evaluable Complete Partial Minimal or no Progression 
patients response response response 
Low grade NHL 24 4 9 7 4 
Intermediate grade NHL 6 1 1 1 3 
High grade NHL 7 0 1 1 5 
CTCL 20 0 9 8 3 
CLL 18 I) 2 5 11 
HCL 14 1 12 1 0 
* NHL non-Hodgkin's lymphoma: CLL. chronic lymphocytic leukemia: CTCL, cutaneous T cell lymphoma: HCL, hairy cell leukemia. 
We began a phase II trial of recombinant leuko- 
cyte A interferon for advanced hairy cell leukemia 
patients based on the reported excellent results 
using natural interferon-c~ (17). Twenty patients 
were treated with intramuscular and/or sub- 
cutaneous injections of recombinant leukocyte A 
interferon at 3 x 106 U daily and 14 have completed 
at least 12 weeks of treatment and are evaluable for 
response (18). There was one complete response 
and 12 partial responses for an overall response rate 
of 93%. All of the partial responders have had a 
substantial improvement in their hematologic pa- 
rameters and at a median follow-up of six months 
not a single patient has relapsed or become refrac- 
tory to interferon. While only one patient has thus 
far demonstrated disappearance of bone marrow 
disease, it does not appear that the absence of hairy 
cells in the bone marrow is necessary for an optimal 
clinical response. The only major toxicity was tran- 
sient myelosuppression during the first week of 
therapy. Immunologic studies have demonstrated 
improvement in natural killer activity and lym- 
phoid subpopulations, both coincident with nor- 
malization of the hematologic parameters. 
Chronic myelogenous leukemia also appears to 
be responsive to interferon-a, with hematologic 
remission reported in 5 of 7 patients treated (19). 
These patients had improved hematologic param- 
eters as well as reduction in the size of enlarged 
spleens and were maintained on 3 × 1@ U of inter- 
feron-a daily or every other day. 
Our phase II studies have demonstrated that 
recombinant leukocyte A interferon has the high- 
est reported response rate for any standard or ex- 
perimental agent in advanced previously treated 
cutaneous T cell lymphoma patients. It also 
establishes recombinant leukocyte A interferon as 
a new non-cross-resistant modality of therapy for 
low grade and intermediate grade histology non- 
Hodgkin's lymphoma. We have also confirmed 
earlier reports that interferon-a is the most active 
single agent for hairy cell leukemia and should be 
considered for therapy when splenectomy is no 
longer effective in controlling the disease. Finally, 
interferon-a has activity in chronic myelogenous 
leukemia. Phase III trials for previously untreated 
patients with non-Hodgkin's lymphoma, cutane- 
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ous T cell lymphoma,:,hairy cell leukemia, and 
chronic myelogenous leukemia patients are clear 
avenues of future investigation. 
Solid tumors 
Antitumor activity for the alpha interferons has 
been quite limited for solid tumors. The greatest 
solid tumor activity has been described for Kabosi's 
sarcoma with approximately a 50% response rate 
(20, 21). Results for breast cancer have been 
mixed, with some responses reported with rather 
crude Cantell preparations and recombinant prep- 
arations of interferon alpha (10, 22, 23) and inter- 
feron beta (24). However, there is also conflicting 
data suggesting no responses for breast cancer pa- 
tients treated with recombinant preparations of 
interferon alpha (25-27). Renal cell carcinoma is 
among the most unresponsiv e tumors to any known 
cytotoxic agents, and approximately a 15% partial 
response rate for interferon alpha has been re- 
ported for patients with renal cell carcinoma. 
These results have been reported for crude inter- 
feron preparations (28) and cloned agents (29, 30). 
Melanoma is another tumor that has no standard 
effective chemotherapy; partial response rates of 
approximately 20 percent have been reported for 
interferon alpha (31, 32). Responses for other com- 
mon solid tumors such as bronchogenic carcinoma 
(33, 34) and colon cancer (35, 36) have been nega- 
tive. Preliminary trials with crude alpha interferon 
preparations from Yugoslavia suggested some ac- 
tivity for head and neck cancers (37, 38); however, 
these results have not been confirmed in the United 
States. 
Monoelonal  antibodies 
Treatment trials 
Clinical trials with monoclonal antibodies in hu- 
mans have been designed to approach preliminary 
questions with respect to the feasibility and toxicity 
of monoclonal antibody therapy and the rationale 
for the use of these reagents (39-56) (Table 2). 
While most of these trials have involved single 
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Table 2. Monoclonal Antibody Clinical Trials 
Disease* Antibody/ Specificity No. of Toxicity Effect Institution Reference 
Class patients 
Bqymphoma Ab89/IgG~, Lymphomas 1 Renal (transient) Transient reduction Dana-Farber 42 
in circulating cells 
B-lymphoma 4D6/IgGzb Idiotype 1 None Complete remission Stanford 43 
36+ months 
B-lymphoma Anti-idiotype/ Idiotype 10 Fever chills, nausea 5 of 10 objective Stanford 44 
IgGt of IgGa~ vomiting, headache, responses 
or lgG~b diarrhea, transient 
dyspnea 
B-CLL Anti-idiotype/ Idiotype 1 Fever, urticaria Transient reduction 
IgG:b and in circulating cells 
IgGi 
B-CLL T101/IgG2~, T65 13 Dyspnea, Transient reduction NCI 39 
hypotensiom fever in circulating ceils 
(101-102° F) 
B-CLL T101/IgG2~, T65 4 Dyspnea, Transient reduction U. Calif. San 40, 41 
hypotension, fever, in circulating cells Diego 
malaise, urticaria 
ATL L17FI2 (anti- Leu-1 i Renal, hepatic Transient reduction Stanford 48 
Leu-1)/lgG,~, (transient) in circulating cells 
CTCL LI7F12/IgG2~ Leu-1 6 Dyspnea, hives Minor remission in 5 Stanford 46, 47 
cutaneous pain of 7 patients 
CTCL TI(/1/IgG_,~, T65 12 Dyspnea, fever Minor remission in NCI 45 
(101-102°F) 4 patients 
CTCL T101/IgG2~, T65 4 Dyspnea, fever Minor remission U. Calif. 41 
San Diego 
T-ALL L17F12/IgG,~ Leu-1 8 Sporadic Transient reduction Stanford 50 
12E7/IgGI T & B cells coagulopathy in circulating cells 
4H9/IgG:~ T cells 
J5/IgG,~ CALLA 
NCI 51 
cALL 4 Fever (101-102 °F) Transient reduction Dana-Farber 52 
in circulating cells 
AML PM/81/IgM NR 3 Fever, back pain Transient reduction Dartmouth 49 
AML-2-23/ NR arthralgia, myalgia in circulating cells 
IgG> NR 
PMN 29/IgM NR 
PMN 6/IgM 
Gastro- 17-1A/IgG2; , NR 20 Urticaria, Limited responses Wistar 54, 55 
intestinal bronchospasm, mild 
hypotension 
Melanoma 9.2.27/IGG,,, 250K 20 Fever, serum None NCI 53 
sickness 
Melanoma R24/IgG3 Gm 12 Urticaria, pruritis, Major tumor Memorial 56 
fever, wheezing, regressions in 3 Sloan- 
vomiting patients Kettering 
* cALL, common acute lymphoblastic leukemia; ATL, adult T cell leukemia-lymphoma; CTCL, cutaneous T cell lymphoma; B-CLL, 
B chronic lymphocytic leukemia; AML, acute myelogenous leukemia; NR, not reported. 
patients or small series of patients, early indica- 
tions are that monoclonal antibody alone may have 
some therapeutic effect, albeit rather limited. 
Forty patients with B cell derived chronic lym- 
phocytic leukemia and cutaneous T cell lymphoma 
have been treated with the T101 or the anti-Leu-1 
antibodies, which recognize a 65 to 69,000 molecu- 
lar weight glycoprotein antigen (39-42, 45-48). Pa- 
tients in these studies have been treated with 1-12 
dosages ranging from 7 to 1000mg (single doses 
ranging from I to 150 rag). Transient reductions in 
circulating leukemia cell counts were described in 
most of these patients; however, they were rarely 
sustained beyond 24 to 48 hours after the com- 
pletion of therapy. A number of patients with cuta- 
neous T cell lymphoma demonstrated transient re- 
ductions in the size of cutaneous skin lesions and 
enlarged lymph nodes. In these studies, in vivo 
antibody localization to tumor cells in the pe- 
ripheral blood, bone marrow, lymph nodes, and 
cutaneous lesions was identified. 
Four patients with acute lymphoblastic leukemia 
were treated with escalating doses of the J5 mono- 
clonal antibody, which binds to the common acute 
lymphoblastic leukemia antigen (CALLA) (52). In 
this study, patients demonstrated transient reduc- 
tions in the circulating leukemia cells immediately 
following therapy with J5 antibody, and they dem- 
onstrated in vivo antibody localization to circulat- 
ing and bone marrow tumor cells. Antimurine anti- 
body responses were not described; however, 
resistance to therapy was mediated in part by anti- 
genic modulation of CALLA (loss of antigen from 
the cell surface membrane) in response to treat- 
ment with J5 antibody. 
A series of IgM monoclonal antibodies recogniz- 
ing glycolipid determinants on acute myelogenous 
leukemia (AML) cells and an IgG2b antibody re- 
cognizing a protein on the surface membrane of 
AML cells were studied in a therapy trial of 3 
patients (49). Transient declines in circulating 
AML cells were reported with evidence of in vivo 
binding to circulating leukemia cells. No antigenic 
modulation was demonstrated with any of these 
antibodies. Human antimurine antibody responses 
were demonstrated in one of three patients. Tox- 
icity was limited to mild fever, back pain, arthral- 
gia, and myalgia. 
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We have recently completed a Phase I trial with 
escalating doses of the antimelanoma monoclonal 
antibody 9.2.27 which recognizes a 250-kd glyco- 
protein/proteoglycan complex (53). Doses from 1 
to 500 mg were administered intravenously to pa- 
tients with disseminated melanoma. Biopsies of 
skin nodules were taken prior to treatment to con- 
firm the presence of the antigen recognized by 
9.2.27. Subsequent biopsies were taken after intra- 
venous administration of 9.2.27 to evaluate the 
presence of antibody binding in vivo on the tumor 
cells. Antibody binding in vivo could be demon- 
strated at doses above 10 rag, by either flow 
cytometry or immunoperoxidase techniques. 
Doses between 200 and 500mg were required to 
saturate all of the antigenic sites on the tumor cells 
on each nodule. Excellent selectivity of in vivo 
localization was seen, with staining of the 
melanoma cells within the nodules and no staining 
of the surrounding non-melanoma tissues. Anti- 
mouse antibody responses were demonstrated in 
one third of the patients, but they did not detecta- 
bly impair the ability of the antibody to localize on 
tumor cells. 
Sears and co-workers (54, 55) have treated 20 
patients with metastatic gastrointestinal malignan- 
cies with the 17-1A IgG~ monoclonal antibody. All 
but 2 patients received a single injection in a dose 
range of 15 to 1000 mg per patient. Mouse antibody 
circulated in the patients' blood for 2 to 50 days and 
was identified in tumor tissues within 1 week of 
administration. Three patients remained tumor- 
free 22, 13, and 10 months after monoclonal anti- 
body therapy. 
Houghton and co-workers have reported 3 of 12 
partial responses in patients with melanoma 
treated with an IgG 3 antibody designated R24, 
which recognizes GD3 , a prominent ganglioside on 
the surface of melanoma cells (56). Interestingly, 
this antibody is cytotoxic in vitro with human com- 
plement and human effector cells, and inflamma- 
tory reactions were observed around tumor sites in 
some of the patients treated with this antibody. 
Toxicity 
Toxicities associated with monoclonal antibody 
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therapy are generally quite mild. Fevers, chills, and 
urticaria are quite common but are not treatment- 
limiting toxicities. Rare patients have developed 
shortness of breath associated with the rapid infu- 
sion of monoclonal antibodies, but this was not 
seen when the antibodies were infused at <5 mg/h 
(39, 41, 44, 45). Occasional patients have de- 
veloped hypotension and tachycardia following the 
infusion of murine monoclonal antibodies (39-41). 
A limited number of patients have developed tran- 
sient reduction in their creatinine clearance and 
elevation of their liver enzymes (42, 48), thought to 
be secondary to immune complexes between 
monoclonal antibody and circulating antigen. In 
conclusion, murine-derived monoclonal antibodies 
can be safely infused; although side effects can be 
expected and are usually mild. 
Anti-idiotype antibodies 
Anti-idiotype monoclonal antibodies differ from 
other types of antibodies in that they are tumor- 
specific in the case of B cell derived tumor cells. 
Immunoglobulin molecules have a unique region in 
their variable region termed the 'idiotype', and the 
idiotype for every immunoglobulin molecule is dif- 
ferent. Since B cell diseases are clonal diseases, 
each tumor cell expresses the same immunoglo- 
bulin molecule; therefore, the idiotype is identical 
on every tumor cell. In this unique situation, the 
idiotype is, therefore, a 'tumor-specific' antigen. A 
group of investigators from Stanford developed a 
monoclonal antibody to the idiotypic determinant 
from a patient with B cell lymphoma who had 
become resistant to cytotoxic drugs and interferon 
(57). The patient had a complete and durable (>3 
years) response to anti-idiotype antibody therapy 
(43). An additional 8 patients with non-Hodgkin's 
lymphoma treated at Stanford and one with 
chronic lymphocytic leukemia treated at the Na- 
tional Cancer Institute have had only partial remis- 
sions or no responses at all. While anti-idiotype 
antibody therapy represents the most specific ap- 
proach to monoclonal antibody therapy for B cell 
derived cancer, there are a number of problems. 
Generating anti-idiotype antibodies is labor inten- 
sive and is not practical on a large scale. Hopefully, 
this process can be refined as new techniques to 
develop these antibodies are developed. In ad- 
dition, anti-idiotype antibodies are patient specific 
and, therefore, can be used to treat only a single 
patient. Two additional problems have recently 
been identified and will limit the therapeutic role 
for anti-idiotype antibody therapy. First, some tu- 
mors are biclonal and would require more than one 
antibody for successful therapy (58, 59). Second, 
the idiotype may be unstable on some patients' 
tumor cells, probably because of somatic mutation 
within the variable region gene (60, 61). 
Problems in antibody therapy 
There are additional obstacles to successful anti- 
body therapy that are common to all murine-de- 
rived monoclonal antibodies. 'Antigenic modula- 
tion' is the loss of antigen from the cell surface 
membrane and occurs within minutes or hours 
after exposure to antibody. During the time that 
the cells are modulated, they no longer bind to 
antibody. The modulated cells will usually reex- 
press the antigen within 24 to 48 hours after the 
antibody infusion has been completed (when re- 
sidual antibody is no longer in the serum). While 
modulation may be a problem for therapy with 
unconjugated free antibody, it may have a positive 
effect on immunoconjugate therapy. The anti- 
tumor effect of immunoconjugates may be greater 
when there is internal modulation of the immu- 
noconjugate-antigen complex, which has been 
demonstrated to take place in a number of systems 
(62, 63). 
Murine-derived monoclonal antibodies can also 
stimulate the development of human antibodies to 
the murine immunoglobulin. This has been a limit- 
ing factor in some of the therapies with monoclonal 
antibodies, particularly in patients who are immu- 
nologically intact (64). This problem might be 
overcome by using low-dose cytotoxic agents with 
the initial antibody infusion to destroy these anti- 
body-producing clones. Human derived monoclo- 
nal antibodies would eliminate this problem, al- 
though responses to the idiotype or allotype of 
human immunoglobulin would still be possible. 
Finally, infusing high doses of antibody (>400 mg) 
at the onset of therapy might induce tolerance (55). 
Another problem with some antibody-tumor 
systems is tumor heterogeneity, with only a portion 
of the tumor cells reacting with a single antibody. 
This might be overcome by using multiple mono- 
clonal antibodies to treat such a tumor. 
Finally, monoclonal antibodies do not appear to 
be very effective in eliminating the tumor cells by 
themselves. Preclinical animal models suggest that 
antibodies conjugated to drugs, toxins, and radio- 
isotopes are more cytotoxic and capable of far 
greater antitumor effects (65, 66). This is a major 
direction of current research. 
Bone marrow clean up 
Another attractive therapeutic application of 
monoclonal antibodies is to 'clean up' autologous 
bone marrow prior to bone marrow transplanta- 
tion. Patients who are in clinical remission will 
often have morphologically undetectable tumor 
cells in their bone marrow which theoretically 
could be detected and destroyed with specific anti- 
bodies and complement (or antibodies conjugated 
to toxins). Most of the obstacles and toxicities with 
monoclonal antibody infusion would be eliminated 
using this technology. Such an approach has been 
reported using B1 monoclonal antibody to clean up 
autologous bone marrow from patients with non- 
Hodgkin's lymphoma (67). Eight patients who had 
relapsed with B cell non-Hodgkin's lymphoma 
were first induced into a minimum disease state 
(with <5% bone marrow involvement with tu- 
mor). Bone marrow was then removed and treated 
with anti-B1 antibody and complement. Patients 
were then treated with intensive chemoradio- 
therapy and were reconstituted with anti-B1 
treated autologous bone marrow. All patients 
achieved a complete clinical response and en- 
grafted by 8 weeks. There was no significant tox- 
icity; B cells were detected by 2 months after trans- 
plantation and normal immunoglobulin levels were 
achieved by 6 months. Six of 8 patients were dis- 
ease free in unmaintained remission for 3 to 20 
months after transplantation. Similar results have 
been reported for the J5 antibody and patients with 
acute lymphoblastic leukemia (68). Results of 
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these trials are preliminary but have clearly demon- 
strated that antibody-treated autologous bone 
marrow is capable of restoring hematopoiesis. 
Long-term disease-free survival will be necessary 
before concluding that these therapies have been 
successful. 
Conclusions 
Interferons have shown activity in a number of 
hematologic malignancies, even in previously 
treated patients; Phase III trials with untreated 
patients appear justified. Responses to interferons 
in most solid tumors, however, have been limited 
in preliminary trials. 
The use of monoclonal antibody immunoconjug- 
ates in the treatment of cancer is in its infancy. 
While much work needs to be done to clarify many 
of the issues surrounding the use of monoclonal 
antibodies, it has been clearly demonstrated in 
both animal tumor models and humans that both 
antibodies alone and antibody conjugates can be 
safely administered with minimal adverse effects 
and, in selected cases, can have therapeutic value. 
Problems such as antigenic modulation, host 
antibody response, and antigenic heterogeneity are 
all major obstacles to safe and effective therapy 
with monoclonal antibodies. These issues are un- 
der investigation in animal models and humans. 
While anti-idiotype antibodies are highly specific 
and have demonstrated excellent responses in a 
small number of patients, problems such as bi- 
clonality of some lymphomas, instability of the 
idiotype, and the difficulty of making 'tailor-made' 
antibodies for individual patients clearly limit the 
role of anti-idiotype therapy. 
Purging of bone marrow with antibodies and 
complement (or coupled to toxins) is limited to 
only a few diseases. However, studies thus far have 
demonstrated that tumor cells can be removed 
from the bone marrow by in vitro treatment with 
antibody and complement, and that this treated 
bone marrow can successfully engraft; a number of 
patients have been rendered disease-free for over 
one year. This may prove to be an important appli- 
cation of monoclonal antibody therapy, and it by- 
12 K.A. Foon 
passes most of the problems with monoclonal anti- 
body infusion therapy described above. 
Perhaps the most important future role for 
monoclonal antibody therapy will be in patients 
with minimal disease in the 'adjuvant' setting, 
where immunoconjugates may localize and destroy 
micrometastatic deposits of tumor cells. We re- 
main cautiously optimistic in exploring these excit- 
ing new approaches to cancer therapy. 
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